All In Biotech

Drug Trial Radar · NCT07096193

Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus

Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta

Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jul 31, 2025

Primary completion

Jan 2030

Study completion Jan 2030

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Jul 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 69 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goals of this clinical study are to first learn more about safety and dosing of the study drug GS-4321 in healthy participants. The study will then learn about the safety and effectiveness of GS-4321 in participants with chronic hepatitis delta (CHD). The primary objective of Phase 1 of this study is to evaluate the safety, tolerability and Pharmacokinetics (PK) of the escalating single doses of GS-4321 administered in healthy participants. The primary objective of Phase 2 of this study is to evaluate the efficacy and safety of the multiple escalating doses of GS-4321 in participants with CHD.

Conditions

  • Chronic Hepatitis Delta

Interventions

  • GS-4321Drug

    Administered subcutaneous (SC) or intravenously IV

  • GS-4321 PlaceboDrug

    Administered SC

  • GS-4321Drug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 and 2: Percentage of Participants With Treatment-emergent Adverse EventsTime frame: Phase 1: First dose up to 44 weeks; Phase 2: First dose up to 96 Weeks plus 48 weeks of posttreatment follow-up
  2. Phase 1 and 2: Percentage of Participants With Treatment-emergent Serious Adverse EventsTime frame: Phase 1: First dose up to 44 weeks; Phase 2: First dose up to 96 Weeks plus 48 weeks of posttreatment follow-up
  3. Phase 1 and 2: Percentage of Participants Experiencing Treatment-emergent Clinical Laboratory AbnormalitiesTime frame: Phase 1: First dose up to 44 weeks; Phase 2: First dose up to 96 Weeks plus 48 weeks of posttreatment follow-up
  4. Phase 1: Serum Pharmacokinetic (PK) parameter; AUC of GS-4321Time frame: First dose up to 24 Weeks
  5. Phase 1: Serum PK Parameter: CmaxTime frame: First dose up to 24 Weeks
  6. Phase 1: Serum PK Parameter: TmaxTime frame: First dose up to 24 Weeks
  7. Phase 1: Serum PK Parameter: t1/2Time frame: First dose up to 24 Weeks
  8. Phase 2: Proportion of Participants with Combined ResponseTime frame: Up to 96 Weeks

Locations

28 sites in 9 countries. Site status is shown where the registry gives one.

  • Investigative Site

    Anaheim, California · Recruiting

  • University of California, San Diego - Altman Clinical and Translational Research Institute

    La Jolla, California · Recruiting

  • University of Louisville, Clinical Trials Unit

    Louisville, Kentucky · Recruiting

  • University of Maryland, Institute of Human Virology, Clinical Research Unit

    Baltimore, Maryland · Recruiting

  • The New York-Presbyterian Hospital

    New York, New York · Recruiting

  • University Multi-profile Hospital for Active Treatment "SofiaMed" 00D

    Sofia, Bulgaria · Recruiting

  • Medizinische Hochschule Hannover, Address: Klinik für Gastroenterologie, Hepatologie, Infektiologie und Endokrinologie

    Hanover, Germany · Recruiting

  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, SC Gastroenterologia ed Epatologia

    Milan, Italy · Recruiting

  • IMSP Spitalul Clinic de Boli Infectioase "Toma Ciorba"

    Chinsinau, Moldova · Recruiting

  • PMSI Clinical Republican Hospital "Timofei Mosneaga"

    Chisinau, Moldova · Recruiting

  • Institutul National De Boli Infectioase Prof. Dr. Matei Bals

    Bucharest, Romania · Recruiting

  • Fundatia Dr. Victor Babes

    Bucharest, Romania · Recruiting

  • Infectious Diseases Institutul National De Boli Infectioase Prof. Matei Bals

    Bucharest, Romania · Recruiting

  • Gastromedica S.R.L.

    Iași, Romania · Recruiting

  • Korea University Ansan Hospital

    Ansan-si, South Korea · Recruiting

  • The Catholic University of Korea Bucheon St. Mary's Hospital

    Bucheon-si, South Korea · Recruiting

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Ditmanson Medical Foundation Chia-Yi Christian Hospital

    Chiayi City, Taiwan · Recruiting

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan · Recruiting

  • Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, Taiwan · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

  • Hacettepe University Faculty of Medicine Hospital Hacettepe Neighborhood

    Ankara, Turkey (Türkiye) · Recruiting

  • Ankara Bilkent City Hospital Oncology Hospital Universiteler Neighborhood

    Ankara, Turkey (Türkiye) · Recruiting

  • Ankara Bilkent City Hospital Universiteler Neighborhood, 1604th Street No: 9,

    Ankara, Turkey (Türkiye) · Recruiting

  • Dicle University Faculty of Medicine

    Diyarbakrir, Turkey (Türkiye) · Recruiting

  • Istabul University-Cerrahpasa Faculty of Medicine Hospital

    Istanbul, Turkey (Türkiye) · Recruiting

  • Koc University Medical Faculty Hospital

    Istanbul, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.